Biomedical company Orchestra BioMed partnered with Medtronic and snagged $110 million in a Series D funding round.
Orchestra BioMed founded in 2017 out of New Hope, Penn. is a biomedical company that brings high-impact medical technology to patients through collaboration and risk-reward partnerships, according to a June 29 press release.
Three takeaways from the collaboration:
- Orchestra BioMed and Medtronic will partner to develop a potential treatment for patients with hypertension who have a cardiac pacemaker.
- The $110 million in financing is managed by RTW Investments, Perspective Advisors, Terumo, SternAegis Ventures and others.
- Orchestra BioMed now has enough capital that it expects to be able to fund operations into 2026.